Your browser doesn't support javascript.
loading
Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer.
Pachynski, Russell K; Kim, Eric H; Miheecheva, Natalia; Kotlov, Nikita; Ramachandran, Akshaya; Postovalova, Ekaterina; Galkin, Ilia; Svekolkin, Viktor; Lyu, Yang; Zou, Qiong; Cao, Dengfeng; Gaut, Joseph; Ippolito, Joseph E; Bagaev, Alexander; Bruttan, Maria; Gancharova, Olga; Nomie, Krystle; Tsiper, Maria; Andriole, Gerald L; Ataullakhanov, Ravshan; Hsieh, James J.
Afiliação
  • Pachynski RK; Molecular Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, Missouri.
  • Kim EH; Division of Urological Surgery, Department of Surgery, Washington University, St. Louis, Missouri.
  • Miheecheva N; BostonGene Corporation, Waltham, Massachusetts.
  • Kotlov N; BostonGene Corporation, Waltham, Massachusetts.
  • Ramachandran A; Molecular Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, Missouri.
  • Postovalova E; BostonGene Corporation, Waltham, Massachusetts.
  • Galkin I; BostonGene Corporation, Waltham, Massachusetts.
  • Svekolkin V; BostonGene Corporation, Waltham, Massachusetts.
  • Lyu Y; Molecular Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, Missouri.
  • Zou Q; Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, P.R. China.
  • Cao D; Department of Pathology and Immunology, Washington University, St. Louis, Missouri.
  • Gaut J; Department of Pathology and Immunology, Washington University, St. Louis, Missouri.
  • Ippolito JE; Department of Radiology, Washington University, St. Louis, Missouri.
  • Bagaev A; BostonGene Corporation, Waltham, Massachusetts.
  • Bruttan M; BostonGene Corporation, Waltham, Massachusetts.
  • Gancharova O; BostonGene Corporation, Waltham, Massachusetts.
  • Nomie K; BostonGene Corporation, Waltham, Massachusetts.
  • Tsiper M; BostonGene Corporation, Waltham, Massachusetts.
  • Andriole GL; Division of Urological Surgery, Department of Surgery, Washington University, St. Louis, Missouri.
  • Ataullakhanov R; BostonGene Corporation, Waltham, Massachusetts. jhsieh@wustl.edu ravshan.ataullakhanov@bostongene.com.
  • Hsieh JJ; Molecular Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, Missouri. jhsieh@wustl.edu ravshan.ataullakhanov@bostongene.com.
Clin Cancer Res ; 27(12): 3478-3490, 2021 06 15.
Article em En | MEDLINE | ID: mdl-33771855
ABSTRACT

PURPOSE:

Multiparametric MRI (mpMRI) has become an indispensable radiographic tool in diagnosing prostate cancer. However, mpMRI fails to visualize approximately 15% of clinically significant prostate cancer (csPCa). The molecular, cellular, and spatial underpinnings of such radiographic heterogeneity in csPCa are unclear. EXPERIMENTAL

DESIGN:

We examined tumor tissues from clinically matched patients with mpMRI-invisible and mpMRI-visible csPCa who underwent radical prostatectomy. Multiplex immunofluorescence single-cell spatial imaging and gene expression profiling were performed. Artificial intelligence-based analytic algorithms were developed to examine the tumor ecosystem and integrate with corresponding transcriptomics.

RESULTS:

More complex and compact epithelial tumor architectures were found in mpMRI-visible than in mpMRI-invisible prostate cancer tumors. In contrast, similar stromal patterns were detected between mpMRI-invisible prostate cancer and normal prostate tissues. Furthermore, quantification of immune cell composition and tumor-immune interactions demonstrated a lack of immune cell infiltration in the malignant but not in the adjacent nonmalignant tissue compartments, irrespective of mpMRI visibility. No significant difference in immune profiles was detected between mpMRI-visible and mpMRI-invisible prostate cancer within our patient cohort, whereas expression profiling identified a 24-gene stromal signature enriched in mpMRI-invisible prostate cancer. Prostate cancer with strong stromal signature exhibited a favorable survival outcome within The Cancer Genome Atlas prostate cancer cohort. Notably, five recurrences in the 8 mpMRI-visible patients with csPCa and no recurrence in the 8 clinically matched patients with mpMRI-invisible csPCa occurred during the 5-year follow-up post-prostatectomy.

CONCLUSIONS:

Our study identified distinct molecular, cellular, and structural characteristics associated with mpMRI-visible csPCa, whereas mpMRI-invisible tumors were similar to normal prostate tissue, likely contributing to mpMRI invisibility.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imageamento por Ressonância Magnética Multiparamétrica Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imageamento por Ressonância Magnética Multiparamétrica Idioma: En Ano de publicação: 2021 Tipo de documento: Article